TOP > R&D INFORMATION > Vision and Strategy
R&D INFORMATION

Vision and Strategy

Global Pharma Innovator To provide innovative pharmaceuticals to the world at the earliest possible time

Aiming for the development of new pharmaceuticals awaited by patients and medical professionals

Diseases that used to be regarded as incurable, such as tuberculosis, as well as those which could only be treated through surgery, such as peptic ulcers, have now been overcome with the advance of medical technologies and the advent of new drugs, saving the lives of many patients and dramatically improving quality of life. On the other hand, there are still a number of diseases for which medical care is not satisfactory or for which cures have not been established. Such unsatisfied medical needs are called “unmet medical needs”. The mission of DAIICHI SANKYO lies in the development of innovative pharmaceuticals capable of addressing these unmet medical needs.

In order to fulfill this mission, DAIICHI SANKYO further refines the pharmaceutical technologies that we have built up over the years to create high-quality and innovative drugs, aiming at creating innovative pharmaceuticals that can contribute to patients across the world at the earliest possible time and continuously.

To achieve our vision for the year 2015

  • Recent years have seen outstanding breakthroughs in various fields of technology. Against this backdrop, pharmaceutical research is also undergoing a paradigm shift. Over the past few years, in particular, the emergence of such scientific fields as genomics and combinatorial chemistry has caused revolutionary shifts, bringing about dramatic changes in studies into the creation of new pharmaceuticals.
  • Realization of our goal to be a Global Pharma Innovator
  • Research and development expenditure / Ratio of research and development expenditure to sales
  • In May 2008, DAIICHI SANKYO acquired U3 Pharma GmbH, German-based company founded by Dr. Ulrich famous for Antibody, to enhance the research for antibody as well as to expand the pipeline.
    As of April 1, 2010, Asubio Pharma focuses core function of drug discovery research from discovery of drug candidate to preclinical study. Asubio Pharma aims further growth as in-house venture of discovery research.
    In addition to them, Ranbaxy's New Drug Discovery Research(NDDR) has been transferred to Daiichi Sankyo India Private Limited (DSIN) as part of Global Research function of Daiichi Sankyo Group and was renamed Daiichi Sankyo Life Science Research Centre in India (RCI). In RCI, we have talented researchers of which enriched the quality and quantity especially in the medicinal chemistry area.
    It is anticipated that the Group would achieve quicker results and better productivity in discovery research.

Meanwhile, such studies require an enormous amount of investment and the critical mass (minimum amount of resources required to achieve the results) for research and development tends to increase.
Aiming to for the realization of the Global Pharma Innovator in 2015 , DAIICHI SANKYO will focus our research and development resources on these areas on a priority basis, as well as making decisions from diversified viewpoints based on science and business perspectives at the GEMRAD (Global Executive Meeting of Research And Development), our supreme body for decision making in terms of global research and development, in order to maximize outcomes.

For details about our research and development strategy:
>> R&D core disease areas